Samsung Biologics reports 30% revenue growth in 2025 driven by plant utilization

South Korea’s Samsung Biologics announced financial results for the fourth quarter and fiscal year 2025, with full-year consolidated revenue growing 30.3% from more than 3.49 trillion South Korean won in 2024 to more than 4.55 trillion South Korean won last year.

The contract development and manufacturing organization (CDMO) attributed the strong financial results to full utilization of Plants 1 through 3 and the ramp-up of Plant 4, which reached full utilization in the third quarter of 2025. The company, which last year became a pure-play CDMO, also brought Plant 5 online at its Bio Campus II in Songdo, Incheon, South Korea, which will begin contributing to revenue in 2026.

“Consistent operations across our existing plants and successful ramp-up of Plant 4 supported reliable delivery for client programs throughout the year,” Samsung Biologics CEO John Rim said in a statement. “Our planned expansion of manufacturing capabilities, including the addition of a U.S. manufacturing footprint, will further enhance supply chain resilience and responsiveness to global client needs.”

Samsung Biologics secured a 1.1 trillion South Korean won manufacturing agreement with an undisclosed European pharmaceutical company in the fourth quarter of 2025, contributing to a cumulative contract value exceeding $21 billion, according to the CDMO.

Last month, the company announced it is acquiring Human Genome Sciences’ biologics manufacturing site in Rockville, Maryland, from GSK for $280 million. It is the CDMO’s first U.S.-based manufacturing facility. Excluding potential contributions from the Maryland site, Samsung Biologics projects 15% to 20% annual revenue growth for 2026.

The Maryland site includes two cGMP manufacturing plants with a combined 60 kL of drug substance capacity — supporting mid- to large-scale programs — with the deal expected to close in the first quarter of 2026, according to Samsung Biologics. The CDMO plans to make additional investments to increase capacity and upgrade technology at the site.

In South Korea, the completion of Plant 5 marked the beginning of its Bio Campus II, adding 180,000 liters of capacity. The facility features digitalized systems designed to boost quality and efficiency, raising the company’s total antibody production capacity to 784,000L. Including the new U.S. site, global production capacity is expected to reach 845,000L.

Samsung Biologics also said it has secured land for Bio Campus III in Songdo, which is expected to support “expanded capabilities across advanced conjugation technologies, as well as cell and gene therapies and antibody vaccines.”

At last week’s J.P. Morgan Healthcare Conference in San Francisco, Rim promised that in 2026 Samsung Biologics “will trigger Plant 6, Bio Campus III" which he described as a future “multimodality” site. “We’re going to be starting to prepare what modalities we will actually have in there,” he added, with the CDMO planning to invest 7 trillion South Korean won to complete Bio Campus III by 2034.

Meanwhile, the company continues to invest in operational systems, digital capabilities, and manufacturing infrastructure, with plans to expand its drug product capabilities including a fully automated pre-filled syringe line slated to be cGMP ready by 2027.